Overview
- Central labs identified 74 not-of-standard-quality samples in December 2025, while state laboratories reported 93, according to the health ministry’s monthly alert.
- Four samples from the North Zone (Ghaziabad) and one each from FDA Ahmedabad, Bihar, and Maharashtra were flagged as spurious, allegedly produced by unauthorized manufacturers using other companies’ brand names.
- Authorities said inquiries into the spurious cases are ongoing and that action will follow under the Drugs and Cosmetics Act and associated rules.
- CDSCO noted that NSQ findings reflect failures on one or more quality parameters for specific tested batches and do not indicate issues with other batches or products.
- The monthly list is posted on the CDSCO portal as part of routine surveillance with state regulators, and November’s tally was higher at 205 NSQ samples (64 central, 141 state), showing month-to-month variation.